RESUMO
The first description of the medical use of licorice appeared in "Shennong Bencao Jing", one of the well-known Chinese herbal medicine classic books dated back to 220-280 AD. As one of the most commonly prescribed Chinese herbal medicine, licorice is known as "Guo Lao", meaning "a national treasure" in China. Modern pharmacological investigations have confirmed that licorice possesses a number of biological activities, such as antioxidation, anti-inflammatory, antiviral, immune regulation, and liver protection. 18ß-glycyrrhetinic acid is one of the most extensively studied active integrants of licorice. Here, we provide an overview of the protective effects of 18ß-glycyrrhetinic acid against various acute and chronic liver diseases observed in experimental models, and summarize its pharmacological effects and potential toxic/side effects at higher doses. We also make additional comments on the important areas that may warrant further research to support appropriate clinical applications of 18ß-glycyrrhetinic acid and avoid potential risks.
Assuntos
Ácido Glicirretínico/análogos & derivados , Hepatopatias/prevenção & controle , Substâncias Protetoras/uso terapêutico , Animais , Ácido Glicirretínico/farmacologia , Ácido Glicirretínico/uso terapêutico , Ácido Glicirretínico/toxicidade , Humanos , Fígado/efeitos dos fármacos , Fígado/metabolismo , Hepatopatias/metabolismo , Substâncias Protetoras/farmacologia , Substâncias Protetoras/toxicidadeRESUMO
AIM: To evaluate the antibacterial and cytotoxic effects of Liquorice as a root canal medicament and to compare its action to the commonly used root canal medicament calcium hydroxide Ca(OH)(2). METHODOLOGY: The antibacterial effect of Liquorice and Ca(OH)(2) either separately or in combination was investigated against Enterococcus faecalis. Agar-well diffusion methods, broth microdilution tests and biofilm susceptibility assays were used to determine the antibacterial activity. Human periodontal ligament fibroblast tissue culture was used to assess the cytotoxicity of the preparations under investigation. RESULTS: Liquorice extract either by itself or in combination with Ca(OH)(2) had a significant inhibitory effect against Enterococcus faecalis compared with that of Ca(OH)(2) alone. The use of Liquorice extract followed by Liquorice/Ca(OH)(2) mixture retained significantly more viable periodontal ligament cells than Ca(OH)(2) , which had a strong lethal effect on the cells. CONCLUSION: Liquorice extract either separately or as Liquorice/Ca(OH)(2) mixture had a potent bactericidal effect against Enterococcus faecalis and retained compatibility with fibroblasts in tissue culture compared to the commonly used root canal medicament Ca(OH)(2).
Assuntos
Ácido Glicirretínico/toxicidade , Glycyrrhiza , Extratos Vegetais/toxicidade , Irrigantes do Canal Radicular/toxicidade , Antibacterianos/farmacologia , Antibacterianos/toxicidade , Materiais Biocompatíveis/farmacologia , Materiais Biocompatíveis/toxicidade , Biofilmes/efeitos dos fármacos , Hidróxido de Cálcio/farmacologia , Hidróxido de Cálcio/toxicidade , Células Cultivadas , Enterococcus faecalis/efeitos dos fármacos , Fibroblastos/efeitos dos fármacos , Ácido Glicirretínico/farmacologia , Humanos , Testes de Sensibilidade Microbiana , Ligamento Periodontal/citologia , Ligamento Periodontal/efeitos dos fármacos , Extratos Vegetais/farmacologia , Raízes de Plantas , Irrigantes do Canal Radicular/farmacologiaRESUMO
Glycyrrhetinic Acid and its salts and esters and Glycyrrhizic Acid and its salts and esters are cosmetic ingredients that function as flavoring agents or skin-conditioning agents - miscellaneous or both. These chemicals may be isolated from licorice plants. Glycyrrhetinc Acid is described as at least 98% pure, with 0.6% 24-OH-Glycyrrhetinic Acid, not more than 20 mu g/g of heavy metals and not more than 2 mu g/g of arsenic. Ammonium Glycyrrhizate has been found to be at least 98% pure and Dipotassium Glycyrrhizate has been found to be at least 95% pure. Glycyrrhetinic Acid is used in cosmetics at concentrations of up to 2%; Stearyl Glycyrrhetinate, up to 1%; Glycyrrhizic Acid, up to 0.1%; Ammonium Glycyrrhizate, up to 5%; Dipotassium Glycyrrhizate, up to 1%; and Potassium Glycyrretinate, up to 1%. Although Glycyrrhizic Acid is poorly absorbed by the intestinal tract, it may be hydrolyzed to Glycyrrhetinic Acid by a beta -glucuronidase produced by intestinal bacteria. Glycyrrhetinic Acid and Glycyrrhizic Acid bind to rat and human albumin, but do not absorb well into tissues. Glycyrrhetinic Acid and Glycyrrhizic Acid and metabolites are mostly excreted in the bile, with very little excreted in urine. Dipotassium Glycyrrhizate was undetectable in the receptor chamber when tested for transepidermal permeation through pig skin. Glycyrrhizic Acid increased the dermal penetration of diclofenac sodium in rat skin. Dipotassium Glycyrrhizate increased the intestinal absorption of calcitonin in rats. In humans, Glycyrrhetinic Acid potentiated the effects of hydrocortisone in the skin. Moderate chronic or high acute exposure to Glycyrrhizic Acid, Ammonium Glycyrrhizate, and their metabolites have been demonstrated to cause transient systemic alterations, including increased potassium excretion, sodium and water retention, body weight gain, alkalosis, suppression of the renin-angiotensis-aldosterone system, hypertension, and muscular paralysis; possibly through inhibition of 11beta -hydroxysteroid dehydrogenase-2 (11beta -OHSD2) in the kidney. Glycyrrhetinic Acid and its derivatives block gap junction intracellular communication in a dose-dependent manner in animal and human cells, including epithelial cells, fibroblasts, osteoblasts, hepatocytes, and astrocytes; at high concentrations, it is cytotoxic. Glycyrrhetinic Acid and Glycyrrhizic Acid protect liver tissue from carbon tetrachloride. Glycyrrhizic Acid has been used to treat chronic hepatitis, inhibiting the penetration of the hepatitis A virus into hepatocytes. Glycyrrhetinic Acid and Glycyrrhizic Acid have anti-inflammatory effects in rats and mice. The acute intraperitoneal LD(50) for Glycyrrhetinic Acid in mice was 308 mg/kg and the oral LD(50) was > 610 mg/kg. The oral LD(50) in rats was reported to be 610 mg/kg. Higher LD(50) values were generally reported for salts. Little short-term, subchronic, or chronic toxicity was seen in rats given ammonium, dipotassium, or disodium salts of Glycyrrhizic Acid. Glycyrrhetinic Acid was not irritating to shaved rabbit skin, but was considered slightly irritating in an in vitro test. Glycyrrhetinic Acid inhibited the mutagenic activity of benzo[a]pyrene and inhibited tumor initiation and promotion by other agents in mice. Glycyrrhizic Acid inhibited tumor initiation by another agent, but did not prevent tumor promotion in mice. Glycyrrhizic Acid delayed mortality in mice injected with Erlich ascites tumor cells, but did not reduce the mortality rate. Ammonium Glycyrrhizate was not genotoxic in in vivo and in vitro cytogenetics assays, the dominant lethal assay, an Ames assay, and heritable translocation tests, except for possible increase in dominant lethal mutations in rats given 2000 mg/kg day(-1) in their diet. Disodium Glycyrrhizate was not carcinogenic in mice in a drinking water study at exposure levels up to 12.2 mg/kg day(-1) for 96 weeks. Glycyrrhizate salts produced no reproductive or developmental toxicity in rats, mice, golden hamsters, or Dutch-belted rabbits, except for a dose-dependent increase (at 238.8 and 679.9 mg/kg day(-1)) in sternebral variants in a study using rats. Sedation, hypnosis, hypothermia, and respiratory depression were seen in mice given 1250 mg/kg Glycyrrhetinic Acid intraperitoneally. Rats fed a powdered diet containing up to 4% Ammonium Glycyrrhizate had no treatment related effects in motor function tests, but active avoidance was facilitated at 4%, unaffected at 3%, and depressed at 2%. In a study of 39 healthy volunteers, a no effect level of 2 mg/kg/day was determined for Glycyrrhizic Acid given orally for 8 weeks. Clinical tests in seven normal individuals given oral Ammonium Glycyrrhizate at 6 g/day for 3 days revealed reduced renal and thermal sweat excretion of Na+ and K+, but carbohydrate and protein metabolism were not affected. Glycyrrhetinic Acid at concentrations up to 6% was not a skin irritant or a sensitizer in clinical tests. Neither Glycyrrhizic Acid, Ammonium Glycyrrhizate, nor Dipotassium Glycyrrhizate at 5% were phototoxic agents or photosensitizers. Birth weight and maternal blood pressure were unrelated to the level of consumption of Glycyrrhizic Acid in 1049 Finnish women with infants, but babies whose mother consumed > 500 mg/wk were more likely to be born before 38 weeks. The Cosmetic Ingredient Review (CIR) Expert Panel noted that the ingredients in this safety assessment are not plant extracts, powders, or juices, but rather are specific chemical species that may be isolated from the licorice plant. Because these chemicals may be isolated from plant sources, however, steps should be taken to assure that pesticide and toxic metal residues are below acceptable levels. The Panel advised the industry that total polychlorobiphenyl (PCB)/pesticide contamination should be limited to not more than 40 ppm, with not more than 10 ppm for any specific residue, and that toxic metal levels must not contain more than 3 mg/kg of arsenic (as As), not more than 0.002% heavy metals, and not more than 1 mg/kg of lead (as Pb). Although the Panel noted that Glycyrrhizic Acid is cytotoxic at high doses and ingestion can have physiological effects, there is little acute, short-term, subchronic, or chronic toxicity and it is expected that these ingredients would be poorly absorbed through the skin. These ingredients are not considered to be irritants, sensitizers, phototoxic agents, or photosensitizers at the current maximum concentration of use. Accordingly, the CIR Expert Panel concluded that these ingredients are safe in the current practices of use and concentration. The Panel recognizes that certain ingredients in this group are reportedly used in a given product category, but the concentration of use is not available. For other ingredients in this group, information regarding use concentration for specific product categories is provided, but the number of such products is not known. In still other cases, an ingredient is not in current use, but may be used in the future. Although there are gaps in knowledge about product use, the overall information available on the types of products in which these ingredients are used and at what concentration indicate a pattern of use. Within this overall pattern of use, the Expert Panel considers all ingredients in this group to be safe.
Assuntos
Qualidade de Produtos para o Consumidor , Cosméticos/toxicidade , Ácido Glicirretínico/toxicidade , Glycyrrhiza/química , Animais , Consenso , Cosméticos/farmacocinética , Ácido Glicirretínico/análogos & derivados , Ácido Glicirretínico/farmacocinética , Humanos , Extratos Vegetais/toxicidade , Medição de Risco , Testes de ToxicidadeRESUMO
Role of alterations of corticosterone metabolism in the expression of the mineralocorticoid activity of glycyrrhizin was explored in rats. While the mineralocorticoid actions of oral glycyrrhizin were not observed in bilaterally adrenalectomized rats and dexamethasone treated rats, the mineralocorticoid actions of glycyrrhizin were fully expressed in bilaterally adrenalectomized rats supplemented with physiological doses of corticosterone. Similar mineralocorticoid actions were observed in rats given glycyrrhizin, deoxycorticosterone and pharmacological doses of corticosterone. Although increases in mean blood pressure were suppressed only by concurrent administration of spironolactone to glycyrrhizin- and deoxycorticosterone-treated rats, increases in mean blood pressure were attenuated by both the glucocorticoid antagonist RU 38486 and spironolactone in pharmacological doses of corticosterone administered rats. Pressor responses to norepinephrine and angiotensin II infusions in rats given deoxycorticosterone and pharmacological doses of corticosterone were significantly higher than in glycyrrhizin-treated rats. These results confirmed the functional significance of 11-beta-hydroxysteroid dehydrogenase in expression of the mineralocorticoid activity of glycyrrhizin.
Assuntos
Glucocorticoides/metabolismo , Ácido Glicirretínico/análogos & derivados , Hipertensão/etiologia , 11-beta-Hidroxiesteroide Desidrogenases , Glândulas Suprarrenais/fisiologia , Adrenalectomia , Aldosterona/sangue , Animais , Pressão Sanguínea/efeitos dos fármacos , Corticosterona/farmacologia , Desoxicorticosterona/farmacologia , Dexametasona/farmacologia , Ácido Glicirretínico/toxicidade , Ácido Glicirrízico , Hidroxiesteroide Desidrogenases/antagonistas & inibidores , Hipertensão/induzido quimicamente , Hipertensão/fisiopatologia , Masculino , Mineralocorticoides/metabolismo , Potássio/sangue , Ratos , Ratos Wistar , Renina/sangue , Espironolactona/farmacologiaAssuntos
Hiperfunção Adrenocortical/induzido quimicamente , Ácido Glicirretínico/análogos & derivados , Abandono do Hábito de Fumar , Feminino , Ácido Glicirretínico/farmacologia , Ácido Glicirretínico/toxicidade , Glycyrrhiza , Ácido Glicirrízico , Humanos , Hipertensão/induzido quimicamente , Pessoa de Meia-Idade , Paresia/induzido quimicamente , Plantas MedicinaisAssuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Ácido Glicirretínico/análogos & derivados , Adrenalectomia , Animais , Anti-Inflamatórios não Esteroides/toxicidade , Aspirina/uso terapêutico , Aspirina/toxicidade , Diclofenaco/uso terapêutico , Diclofenaco/toxicidade , Combinação de Medicamentos , Avaliação Pré-Clínica de Medicamentos , Feminino , Ácido Glicirretínico/uso terapêutico , Ácido Glicirretínico/toxicidade , Ácido Glicirrízico , Inflamação/induzido quimicamente , Inflamação/tratamento farmacológico , Dose Letal Mediana , Masculino , Camundongos , Ratos , SolubilidadeAssuntos
Glycyrrhiza , Fitoterapia/história , Plantas Medicinais , 11-beta-Hidroxiesteroide Desidrogenases , Corticosteroides/metabolismo , Animais , Ásia , Doces , Edema/induzido quimicamente , Europa (Continente) , Expectorantes/uso terapêutico , Aromatizantes/farmacologia , Gastroenteropatias/tratamento farmacológico , Ácido Glicirretínico/análogos & derivados , Ácido Glicirretínico/isolamento & purificação , Ácido Glicirretínico/farmacologia , Ácido Glicirretínico/uso terapêutico , Ácido Glicirretínico/toxicidade , Ácido Glicirrízico , História do Século XX , História Antiga , Humanos , Hidroxiesteroide Desidrogenases/antagonistas & inibidores , Hipertensão/induzido quimicamente , Natriurese/efeitos dos fármacos , Extratos Vegetais/história , Extratos Vegetais/farmacologia , Extratos Vegetais/uso terapêutico , Extratos Vegetais/toxicidade , Plantas Tóxicas , Ratos , Sede/efeitos dos fármacos , NicotianaRESUMO
In experiments on various animals glyderinine, a derivative of glycyrrhizic acid isolated from Glycyrrhiza glabra, was found to exert a pronounced anti-inflammatory effect exceeding that of hydrocortisone and amidopyrine. The mechanism of the anti-inflammatory effect was to a certain degree related to the adrenal cortex, suppression of vascular permeability and antagonism to inflammation as well. Similarly to other anti-inflammatory agents, glyderinine possesses analgesic and antipyretic properties, but unlike them it fails to suppress hemopoiesis and to cause ulceration of the gastrointestinal mucosa. The drug is of low toxicity and exerts the antiallergic effect. Glyderinine was successfully tried and recommended for a wide use as an ointment for treating skin diseases.
Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Ácido Glicirretínico/análogos & derivados , Xantenos/farmacologia , Xantonas , Glândulas Suprarrenais/fisiologia , Adrenalectomia , Animais , Anti-Inflamatórios não Esteroides/toxicidade , Artrite/induzido quimicamente , Artrite/tratamento farmacológico , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos , Ácido Glicirretínico/uso terapêutico , Ácido Glicirretínico/toxicidade , Camundongos , Peritonite/induzido quimicamente , Peritonite/tratamento farmacológico , Ratos , Fatores de Tempo , Xantenos/uso terapêuticoRESUMO
The derivatives of glycyrrhizin acid--dihydrazidohydrazose of glycyrrhizin acid (DHGA), DHGA plus benzaldehyde, DHGA plus 5-nitrofurfurol, DHGA plus furfurol, glycyrrhizin acid, methylmethioninsulfonium-glycyrrhizinate, sodium salt of 18-glycyrrhetic acid, and potassium salt of glycyrrhizin acid--show a pronounced anti-inflammatory action, inhibit the development of histamine-, serotonin-, bradykinin-, and formalin-induced edemas, barrier function of an inflammatory focus, lower vascular permeability, the granulemic sac weight and exudate amount. The anti-inflammatory action of the compounds remains unchanged under adrenalectomy. By antiphlogistic activity, the derivatives in question compare very favourably to butadion and hydrocortisone, and are similar to prednisolone.